亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

医学 乌斯特基努马 银屑病 安慰剂 银屑病面积及严重程度指数 临床终点 内科学 加药 随机化 体表面积 斑块性银屑病 随机对照试验 不利影响 临床试验 皮肤病科 阿达木单抗 疾病 病理 替代医学
作者
Kristian Reich,Kim Papp,Andrew Blauvelt,Richard Langley,April W. Armstrong,Richard B. Warren,Kenneth B. Gordon,Joseph F. Merola,Yukari Okubo,Cynthia Madden,Maggie Haitian Wang,Christopher L. Cioffi,Veerle Vanvoorden,Mark Lebwohl
出处
期刊:The Lancet [Elsevier BV]
卷期号:397 (10273): 487-498 被引量:215
标识
DOI:10.1016/s0140-6736(21)00125-2
摘要

Background There is an unmet need for a treatment for psoriasis that results in complete skin clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. We aimed to compare the efficacy and safety of bimekizumab with placebo and ustekinumab in patients with moderate to severe plaque psoriasis over 52 weeks. Methods BE VIVID was a multicentre, randomised, double-blind, active comparator and placebo controlled phase 3 trial done across 105 sites (clinics, hospitals, research units, and private practices) in 11 countries in Asia, Australia, Europe, and North America. Adults aged 18 years or older with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index [PASI] score ≥12, ≥10% body surface area affected by psoriasis, and Investigator's Global Assessment [IGA] score ≥3 on a five point scale) were included. Randomisation was stratified by geographical region and previous exposure to biologics; patients, investigators, and sponsors were masked to treatment assignment. Patients were randomly assigned (4:2:1) using an interactive response technology to bimekizumab 320 mg every 4 weeks, ustekinumab 45 mg or 90 mg (baseline weight-dependent dosing) at weeks 0 and 4, then every 12 weeks, or placebo every 4 weeks. At week 16, patients receiving placebo switched to bimekizumab 320 mg every 4 weeks. All study treatments were administered as two subcutaneous injections. Coprimary endpoints were the proportion of patients with 90% improvement in the PASI (PASI90) and the proportion of patients with an IGA response of clear or almost clear (score 0 or 1) at week 16 (non-responder imputation). Efficacy analyses included the intention-to-treat population; safety analysis included patients who received at least one dose of study treatment. This trial was registered at ClinicalTrials.gov, NCT03370133 (completed). Findings Between Dec 6, 2017, and Dec 13, 2019, 735 patients were screened and 567 were enrolled and randomly assigned (bimekizumab 320 mg every 4 weeks n=321, ustekinumab 45 mg or 90 mg every 12 weeks n=163, placebo n=83). At week 16, 273 (85%) of 321 patients in the bimekizumab group had PASI90 versus 81 (50%) of 163 in the ustekinumab group (risk difference 35 [95% CI 27–43]; p<0·0001) and four (5%) of 83 in the placebo group (risk difference 80 [74–86]; p<0·0001). At week 16, 270 (84%) patients in the bimekizumab group had an IGA response versus 87 (53%) in the ustekinumab group (risk difference 30 [95% CI 22–39]; p<0·0001) and four (5%) in the placebo group (risk difference 79 [73–85]; p<0·0001). Over 52 weeks, serious treatment-emergent adverse events were reported in 24 (6%) of 395 patients in the bimekizumab group (including those who switched from placebo at week 16) and 13 (8%) of 163 in the ustekinumab group. Interpretation Bimekizumab was more efficacious than ustekinumab and placebo in the treatment of moderate to severe plaque psoriasis. The bimekizumab safety profile was consistent with that observed in previous studies. Funding UCB Pharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Kevin完成签到,获得积分10
23秒前
28秒前
辉哥发布了新的文献求助10
35秒前
49秒前
55秒前
董可以发布了新的文献求助10
58秒前
英俊的铭应助董可以采纳,获得10
1分钟前
curtain完成签到,获得积分10
1分钟前
大个应助科研通管家采纳,获得10
1分钟前
MchemG应助科研通管家采纳,获得10
1分钟前
所所应助科研通管家采纳,获得10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
1分钟前
落寞书易完成签到 ,获得积分10
1分钟前
2分钟前
现实的小霸王完成签到,获得积分10
2分钟前
2分钟前
Xw完成签到,获得积分10
2分钟前
科研通AI5应助迷人问兰采纳,获得10
2分钟前
Hello应助LSH970829采纳,获得10
3分钟前
Xw发布了新的文献求助10
3分钟前
寒冷的应助核桃采纳,获得30
3分钟前
wen发布了新的文献求助10
3分钟前
隐形曼青应助科研通管家采纳,获得10
3分钟前
科研通AI2S应助科研通管家采纳,获得10
3分钟前
MchemG应助科研通管家采纳,获得10
3分钟前
wen完成签到,获得积分10
3分钟前
3分钟前
3分钟前
4分钟前
yar应助wen采纳,获得10
4分钟前
核桃发布了新的文献求助30
4分钟前
迷人问兰发布了新的文献求助10
4分钟前
4分钟前
牛牛完成签到 ,获得积分10
5分钟前
时间煮雨我煮鱼完成签到,获得积分10
5分钟前
Plum22发布了新的文献求助10
5分钟前
BiuBiu怪完成签到,获得积分10
6分钟前
bkagyin应助陈苗采纳,获得10
6分钟前
核桃发布了新的文献求助10
6分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990084
求助须知:如何正确求助?哪些是违规求助? 3532108
关于积分的说明 11256447
捐赠科研通 3271016
什么是DOI,文献DOI怎么找? 1805171
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228